Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Hodgkin Disease 2

Interventions

pembrolizumab 66Carboplatin 65Paclitaxel 54Magnetic Resonance Spectroscopy 45Cisplatin 45Specimen Handling 43Gemcitabine 36Docetaxel 31Bevacizumab 31Leucovorin 29Doxorubicin 29Dexamethasone 28Fluorouracil 27Pemetrexed 26Cyclophosphamide 26Oxaliplatin 24Radiation 23durvalumab 22Radiotherapy 22Letrozole 22Etoposide 22Nivolumab 21Irinotecan 21Vincristine 20Rituximab 20Capecitabine 20Taxes 19Prednisone 19Lenalidomide 19130-nm albumin-bound paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Granulocyte Colony-Stimulating Factor × 30 days × Clear all
NCT04685616 2026-06-02

RADAR

University College, London

Phase 3 Recruiting
1,042 enrolled
Lymphoid

Hodgkin Disease

NCT03907488 2026-06-01

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
994 enrolled 11 charts 1 FDA
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡